Introduction: Gastric cancer (GC) is a leading cause of cancer-related death worldwide, with poor prognosis due to late diagnosis and limited treatment options. The ABCA family of transporters is involved in key cellular processes, including drug resistance and cancer progression. Alterations in the expression of ABCA genes may influence gastric cancer biology, making them potential targets for new diagnostic and therapeutic approaches. Objectives: This study aims to evaluate the expression profile of ABCA transporters in gastric cancer tissues to better understand their role in disease progression. Methods: We analyzed the expression of ABCA family genes in paired tumor and adjacent tissue samples from 42 patients (CAAE: 47580121.9.0000.5634). Total RNA was extracted using TRIzol® and evaluated for integrity using the 2200 TapeStation System (Agilent Technologies). RNA-seq was conducted on the NextSeq® platform (Illumina®, USA). The raw data was converted to FASTQ format using Reporter software, and the reads were mapped using the Salmon tool, with annotation based on the hg38 version of GENCODE. The identified reads were quantified and imported into the R statistical environment via the tximport library, and the significance of differences was determined using the Wilcoxon-Mann-Whitney test. Differential gene expression of all ABCA family genes between adjacent and cancer tissues was analyzed through RNA-Seq. Results: The analysis revealed a significant increase in the expression of the ABCA1 gene in cancerous tissue samples. On the other hand, genes ABCA6, ABCA8, and ABCA9 showed reduced expression in comparison to non-neoplastic tissues. No significant differences in expression were observed for ABCA10, ABCA12, ABCA13, ABCA2, ABCA3, ABCA4, ABCA5, and ABCA7 between gastric cancer and adjacent tissues. The Receiver Operating Characteristic (ROC) curve was generated for the genes ABCA1, ABCA6, ABCA8, and ABCA9, which showed significant differences in expression between cancerous and adjacent tissues. The Area Under the Curve (AUC) values were 0.81 for ABCA1, 0.71 for ABCA6, 0.85 for ABCA8, and 0.70 for ABCA9. Conclusion: The ABCA family genes are dysregulated in gastric cancer, exhibiting high expression of ABCA1 and low expression of ABCA6, ABCA8, and ABCA9. These alterations may contribute to the development and progression of gastric cancer, providing potential therapeutic targets for future interventions.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
